CN1527704B - 治疗眼病的组合物和微管蛋白结合剂用法 - Google Patents

治疗眼病的组合物和微管蛋白结合剂用法 Download PDF

Info

Publication number
CN1527704B
CN1527704B CN028139917A CN02813991A CN1527704B CN 1527704 B CN1527704 B CN 1527704B CN 028139917 A CN028139917 A CN 028139917A CN 02813991 A CN02813991 A CN 02813991A CN 1527704 B CN1527704 B CN 1527704B
Authority
CN
China
Prior art keywords
eye
ocular
revascularization
administration
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028139917A
Other languages
English (en)
Chinese (zh)
Other versions
CN1527704A (zh
Inventor
戴维·谢里斯
马克·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxi Gene Inc
Original Assignee
Oxi Gene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxi Gene Inc filed Critical Oxi Gene Inc
Publication of CN1527704A publication Critical patent/CN1527704A/zh
Application granted granted Critical
Publication of CN1527704B publication Critical patent/CN1527704B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CN028139917A 2001-07-13 2002-07-15 治疗眼病的组合物和微管蛋白结合剂用法 Expired - Fee Related CN1527704B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US38622701P 2001-07-13 2001-07-13
US60/386,227 2001-07-13
US37784502P 2002-05-03 2002-05-03
US37784702P 2002-05-03 2002-05-03
US37755602P 2002-05-03 2002-05-03
US60/377,845 2002-05-03
US60/377,556 2002-05-03
US60/377,847 2002-05-03
PCT/US2002/022449 WO2003006002A1 (en) 2001-07-13 2002-07-15 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases

Publications (2)

Publication Number Publication Date
CN1527704A CN1527704A (zh) 2004-09-08
CN1527704B true CN1527704B (zh) 2011-05-18

Family

ID=32034390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028139917A Expired - Fee Related CN1527704B (zh) 2001-07-13 2002-07-15 治疗眼病的组合物和微管蛋白结合剂用法

Country Status (8)

Country Link
EP (1) EP1406600A4 (enExample)
JP (2) JP2004536847A (enExample)
KR (1) KR20040030042A (enExample)
CN (1) CN1527704B (enExample)
CA (1) CA2453442C (enExample)
NZ (1) NZ575466A (enExample)
WO (1) WO2003006002A1 (enExample)
ZA (1) ZA200400210B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP4005048B2 (ja) * 2003-04-09 2007-11-07 日信工業株式会社 炭素繊維複合材料およびその製造方法
CA2766178A1 (en) * 2009-07-02 2011-01-06 Oxigene, Inc. Combretastatins for prevention of posterior capsule opacification
CN106822083A (zh) 2009-08-27 2017-06-13 生物学特性有限公司 用于治疗增生性疾病的联合疗法
JP2013502440A (ja) * 2009-08-27 2013-01-24 バイオノミックス リミテッド 黄斑変性の治療
SG11201500688XA (en) * 2012-08-02 2015-02-27 Amril Ag Natural rubber containing nanocarbon
CN113577020B (zh) * 2021-08-16 2022-09-23 海南鑫开源医药科技有限公司 一种玻璃体腔内注射剂、其制备方法及应用
CN113520995B (zh) * 2021-08-16 2023-03-10 海南鑫开源医药科技有限公司 一种离子敏感型眼用原位凝胶、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
DE69942645D1 (en) * 1998-01-09 2010-09-16 Body Corporate Of The State Of Synthese von combretastatin a-4 prodrugs
GB9903404D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
WO2000048606A1 (en) * 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US6670344B2 (en) * 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts

Also Published As

Publication number Publication date
WO2003006002A9 (en) 2004-07-22
ZA200400210B (en) 2005-06-29
JP2004536847A (ja) 2004-12-09
CA2453442A1 (en) 2003-01-23
WO2003006002A8 (en) 2004-05-27
WO2003006002A1 (en) 2003-01-23
JP2009132738A (ja) 2009-06-18
CA2453442C (en) 2011-02-01
NZ575466A (en) 2011-01-28
CN1527704A (zh) 2004-09-08
EP1406600A1 (en) 2004-04-14
EP1406600A4 (en) 2007-06-06
KR20040030042A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
US20030181531A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
Melamed et al. Short-term effect of argon laser trabeculoplasty in monkeys
Cardillo et al. Single intraoperative application versus postoperative mitomycin C eye drops in pterygium surgery
Nuyts et al. Histopathologic effects of mitomycin C after trabeculectomy in human glaucomatous eyes with persistent hypotony
TWI335819B (en) Use of oculosurface selective glucocorticoid in the treatment of dry eye
RU2359693C2 (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
JP2009132738A (ja) 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
TW200302226A (en) Methods for treating ocular neovascular diseases
US20100190734A1 (en) Method of treating dry eye disease with azithromycin
CN110869045B (zh) 包含i型胶原及色素上皮衍生因子肽作为有效成分的预防或治疗新生血管性疾病的药物组合物
US20180369172A1 (en) Methods and compositions for promoting wound healing with decreased scar formation after glaucoma filtration surgery
Yildirim et al. Evaluation of color-changing effect and complications after Nd: YAG laser application on iris surface
NO328085B1 (no) Anvendelse av staurosporinderivater for fremstilling av et medikament for behandling av okulaere neovaskulaere sykdommer
RU2354398C2 (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
AU2008202468B2 (en) Compositions and Methods of Administering Tubulin Binding Agents for the Treatment of Ocular Diseases
GARIANO et al. Retinal toxicity of the antimetabolite 5-fluorouridine 5'-monophosphate administered intravitreally using multivesicular liposomes
CN103705551A (zh) 一种新型白蒺藜皂苷玻璃体腔注射给药系统及其应用
AU2002322494A1 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
JP2004536847A5 (enExample)
CN109789115A (zh) 用于治疗眼疾的方法
JP2005521681A (ja) 尿素および尿素誘導体を使用した眼科疾患の治療方法
RU2359648C2 (ru) Способ лечения меланомы хориоидеи
Kralinger et al. Intravitreal acetylsalicylic acid in silicone oil: pharmacokinetics and evaluation of its safety by ERG and histology
CN116407496B (zh) 一种包含青蒿素前体药物的滴眼液及其制备方法
JP2004331502A (ja) 視神経細胞保護剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110518

Termination date: 20160715